Skip to main content

Remote Job Finders (RJF)

J&J hands lymphoma bispecific CAR T back to AbelZeta

Johnson & Johnson secured rights to prizlon-cel in 2023 for $245 million upfront. The asset in June last year showed a 100% response rate as a second-line option in a Phase 1b study for 10 patients with relapsed or refractory large B cell lymphoma.

Italian biotech gains momentum as VC funding, tech transfer environment improve

Despite ranking among the world’s top scientific producers, Italy has struggled to turn research into startups. Now, stronger tech transfer offices, private capital and returning scientists are pushing the country toward a more mature innovation economy.
Scroll to top